Oral GLP-2
Short Bowel Syndrome
Discovery/PreclinicalActive; Collaboration with OPKO Health
Key Facts
Indication
Short Bowel Syndrome
Phase
Discovery/Preclinical
Status
Active; Collaboration with OPKO Health
Company
About Entera Bio
Entera Bio is a clinical-stage biotech focused on transforming injectable peptide therapies into convenient oral tablets using its proprietary N-Tab® drug delivery platform. The company's strategy de-risks development by targeting well-characterized peptides like PTH, with its lead asset, EB613 for osteoporosis, having completed a positive Phase 2 study and a streamlined Phase 3 protocol submitted in early 2026. Backed by a seasoned management team and strategic partnerships, Entera aims to redefine standards of care by improving patient adherence and enabling earlier therapeutic intervention.
View full company profile